95 results about "Upper digestive tract" patented technology

The invention provides a hydrogel-type sustained-release preparation comprising (1) at least one drug, (2) an additive which insures a penetration of water into the core of the preparation and (3) a hydrogel-forming polymer, wherein said preparation is capable of undergoing substantially complete gelation during its stay in the upper digestive tract such as stomach and small intestine and is capable of releasing the drug in the lower digestive tract including colon.By the preparation of the invention, the drug is efficiently released and absorbed even in the colon so that a steady and sustained release effect can be achieved.

The invention provides a hydrogel-type sustained-release preparation comprising (1) at least one drug, (2) an additive which insures a penetration of water into the core of the preparation and (3) a hydrogel-forming polymer, wherein said preparation is capable of undergoing substantially complete gelation during its stay in the upper digestive tract such as stomach and small intestine and is capable of releasing the drug in the lower digestive tract including colon. By the preparation of the invention, the drug is efficiently released and absorbed even in the colon so that a steady and sustained release effect can be achieved.

The invention relates to an optical fiber detecting probe head, in particular to an optical fiber detecting probe head for a portable raman spectrometer. The optical fiber detecting probe head for the portable raman spectrometer is characterized by comprising a probe head component and a plurality of collecting optical fibers (9), wherein one ends of the collecting optical fibers (9) are simultaneously connected with the probe head component, and another ends of the collecting optical fibers (9) are simultaneously connected with an FC (fiber channel) probe head; and the optical fiber detecting probe head for the portable raman spectrometer further comprises an exciting optical fiber (10), wherein one end of the exciting optical fiber (10) is connected with the probe head component, and another end of the exciting optical fiber (10) is connected with an SMA905 interface. Therefore, the optical fiber detecting probe head has the advantages that the optical fiber detecting probe head is mini, efficient, and suitable for the clinic detection of the early digestive tract cancer, and the raman light collecting efficiency at the side wall of the upper digestive tract can be improved.

The invention relates to an effervescent tablet for preparing a mouth rinsing solution, wherein the effervescent tablet exhibits a high release rate of budesonide. A high availability of the active ingredient during use as a mouth rinsing solution on the inflamed mucosa of the upper digestive tract is thereby achieved. The advantage of the formulation according to the invention lies in the bioavailability comparable to oral forms of administration, which allows the formulation to be used safely over an extended period of time.

The invention discloses an automatic focus retaining method for an upper digestive tract endoscopic image. The method comprises the following steps: collecting and preprocessing digestive tract data; a large part classification model M-Net is constructed; a focus detection model is constructed to carry out focus detection on the large parts; constructing a focus separation and induction device, numbering the input pictures according to focuses, and respectively inducing the input pictures into different folders; constructing a mucous membrane visualization model, and removing invalid pictures or artifact pictures with poor visualization degree; constructing a 26-part positioning model, and performing 26-part classification on the upper digestive tract; and automatically outputting a picture reserving result. According to the method, the high-quality picture of the abnormal lesion of the upper digestive tract can be automatically reserved finally, and the specific part can be quickly positioned. According to the method, an endoscopic physician can be helped to quickly and automatically position and retain images of abnormal focuses of the upper digestive tract, the integrity and effectiveness of the images reserved by an endoscopic report are well improved, the homogenization of the comprehensive quality of the endoscopic report is realized, and the guidance treatment value and follow-up visit value of the endoscopic report are consolidated.

The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of long chain fatty acid to the colon by bypassing the upper digestive tract.

An oral dosage form of a pharmaceutical composition for managing diabetes in a subject is provided, which comprises a core, a controlled membrane film, and an outer film. The core comprises a first antidiabetic agent. The controlled membrane film coats the core tablet and can realize a controlled release of the first antidiabetic agent from the core into a portion of a digestive tract of the subject corresponding to a stomach and an upper gastrointestinal tract after the pharmaceutical composition is orally administered to the subject. The controlled membrane film comprises at least one controlling polymer, each selected from an Eudragit polymer, an Aquacoat polymer, or an Ethocel polymer. The outer film comprises a second antidiabetic agent, and coats the controlled membrane film. A method for manufacturing an oral dosage form of a pharmaceutical composition is also provided.

The invention discloses a suturing-free anastomosis device for a digestive tract. The suturing-free anastomosis device comprises a pair of matched circular rings, namely a first circular ring and a second circular ring, wherein more than two semispherical first and second magnets are respectively embedded into ring planes of the circular rings; the inner diameter of the first circular ring is greater than that of the second circular ring; the first circular ring and the second circular ring are respectively arranged at two broken ends of the digestive tract; tail end tissues at the broken ends are inwards turned; magnetic poles on the bottom surfaces of the first magnets and the second magnets are opposite; the first magnets and the second magnets attract to each other, so that the first circular ring and the second circular ring attract to each other to clamp the tail end tissues to be perfectly matched; when the first circular ring and the second circular ring attract to each other, every two of the first magnets and the second magnets attract to each other to form a ball; under the attraction force among the magnets, suturing-free anastomosis between the broken ends of the digestive tract is finished; after the anastomosis is finished, the tail ends of the inwards turned tissues are sunken towards one side of the second circular ring; meanwhile, the circular rings are gradually disintegrated in the digestive tract, and the attracted magnets attract to each other to form the balls; the balls and disintegrated degradable material fragments are together discharged out of a body under peristalsis of the digestive tract. The suturing-free anastomosis device is easy to operate and reliable in effect.

A diarrhea-relieving with astringents colon-positioning enteric-coated pharmaceutical preparation and the preparation method thereof belong to a colon-positioning enteric-coated pharmaceutical preparation technical field. Active ingredients of the preparation are montmorillonite and Rhizome Rhodesia; adopting coating treatment with colon coating materials, the medicine does not disintegrate and release on an upper digestive tract; the preparation arrives at a colon part and disintegrates rapidly and releases the medicine in order that the medicine can be contacted with an intestinal focus part directly to improve curative effect.

The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a monoamine reuptake inhibitor such as buproprion.

The invention discloses a digestive tract detector for the digestive internal medicine department. The detector comprises a cannula, a probe head is installed at one end of the cannula, an installation plate is installed at the other end of the cannula, a display screen is installed at the upper end of the side surface of the installation plate, and a control switch is installed on the side surface of the installation plate at the lower side of the display screen. The digestive tract detector for the digestive internal medicine department is simple in structure; the cannula and the probe head are inserted into the detection position of the digestive tract, the peristaltic pressure and temperature of the digestive tract are detected by a pressure sensor and a temperature sensor in the probe head, and therefore the detector is adopted to assist in completing the diagnosis of digestive tract diseases and postoperative function evaluation and is safe without causing injuries; a wire cylinder drives a push plate to push an adjusting rod to move towards a first end pipe, so that the distance between angles corresponding to the first end pipe and a second end pipe is reduced, and therefore the whole probe head is bent to pass through the bent part of the digestive tract and reaches a preset detection position conveniently; thus, accurate detection data are obtained, and the detector is convenient to use.

The invention discloses a traction type capsule endoscopy which comprises a capsule endoscopy body. The traction type capsule endoscopy is characterized in that one end of the capsule endoscopy body is a non-free end which is provided with a traction flexible wire, the other end of the capsule endoscopy body is a free end, and the traction flexible wire is connected with the capsule endoscopy body through a connecting mechanism. Compared with the prior art, the traction type capsule endoscopy has the advantages that direct contact of the capsule endoscopy body and the upper digestive tract is avoided so that the capsule endoscopy body can be conveniently and repeatedly used, one-time detection cost of a patient is lowered, and popularization of the capsule endoscopy at various areas is facilitated; the traction type capsule endoscopy is small in size, the outer surface is smooth, adverse reactions of the patient in the detection process are reduced to a large extent, and unnecessary damage to the upper digestive tract is avoided.

The invention belongs to the technical field of postoperative rehabilitation devices, and particularly relates to a device beneficial for rehabilitation after an upper digestive tract tumor operation.In order to solve the problems that for existing postoperative rehabilitation, patients generally need help of others with massages and turnovers, nursing workers are stressed, and recovery of the patients is easily affected, the following scheme is proposed: the device beneficial for rehabilitation after the upper digestive tract tumor operation comprises a base and a bed board located over thebase, wherein a first motor is fixedly connected with the top of the base, a rotating shaft is fixedly connected with an output shaft of the first motor, a rocker is fixedly connected with one side ofthe top end of the rotating shaft, two fixing blocks are fixedly connected with the bottom of the bed board, and second sliding grooves are formed in both the sides, close to each other, of the two fixing blocks. According to the device beneficial for rehabilitation after the upper digestive tract tumor operation, the rotating shaft and the rocker are rotated through the first motor, when slidingin a first sliding groove, the rocker pushes a sliding block to slide in the second sliding grooves back and forth repeatedly, and the sliding block squeezes massage rods when sliding, so that the massage rods vertically slide in third sliding grooves to massage the back of a patient.

The invention discloses a novel application of jatrorrhizine for treating candida albicans infectious diseases. The jatrorrhizine can be extracted from plants of coptis roots, amur corktree barks, caulis mahoniae and the like. The study shows that half bacteriostasis concentration of the jatrorrhizine to candida albicans is 139+ / -21mg / L, and effective dose of the jatrorrhizine for enhancing body resistibility of a low immune function mouse to the candida albicans is 30mg / Kg. The jatrorrhizine and pharmaceutically acceptable salts, esters or sugars, excipients and the like are utilized for preparing medicines for treating diseases caused by the fact that the candida albicans infect human and livestock, and the jatrorrhizine can be applied to, but is not limited to, medicines for treating human skins, mucous membranes, internal organs or nervous centralis candidiasis, livestock upper digestive tract mycoses and the like. The jatrorrhizine and the pharmaceutically acceptable salts, esters or sugars and excipients and the like can be prepared to be injection, oral administration and external preparations and dosage forms thereof which are pharmaceutically acceptable such as injections, tablets, capsules, liniments, pastes, smearing agents, emulsions, nanoparticle emulsions, and the like.

A method of inserting a treatment tool includes: making a puncture needle project from a first channel of an endoscope and puncturing an upper digestive tract to place a distal end of a needle tube of the puncture needle inside a biliary tract while observing an ultrasound image; inserting a guide wire into the biliary tract via the needle tube and making a distal end of the guide wire extend out from a duodenal papilla into a duodenum; placing a distal end portion of the endoscope in vicinity of the duodenal papilla while keeping the distal end of the guide wire extending out from the duodenal papilla while observing a captured image; pulling the guide wire extending out from the duodenal papilla into a second channel having a raised angle of the treatment tool larger than that of the first channel; and inserting the treatment tool inside the biliary tract via the guide wire.

A sucralfate self-emulsifying microcapsule is composed of solid powder or particles prepared from sucralfate, lipid, surfactant, and a wall material; the capsule core is composed of a sucralfate self-emulsifying composition, and the capsule core is wrapped by a wall material. The microcapsule is prepared through a spray drying method and a spray-coagulation method. The provided microcapsule is a novel upper digestive tract mucosa protective agent. The microcapsule has the advantages of wide range of indication, more unique and comprehensive action mechanism, and no prominent clinical side effect. Moreover, the frequency of daily drug taking is reduced by 50%, compared with conventional dosage forms. The microcapsule is user-friendly. The compliance of patients is increased, and the microcapsule is beneficial for more clinical patients. The particles in microcapsule are small, have a self-emulsifying function, are not affected by the gastrointestinal functions of patients, and can be well absorbed, and thus a good treatment effect can be achieved. The microcapsule is especially suitable for children, the old, and the patients, who have bad gastrointestinal functions, and can reduce the burden on stomach and intestines.

The invention relates to a digestive tract detection device, which is a system capable of detecting early functional abnormity of a digestive tract on the basis of positioning principle. The system comprises a positioning capsule (4) and a signal receiving system. The positioning capsule (4) comprises a power supply (5), a signal storage card (6), a signal amplifier (8), an inner transducer (9) and a shell; and the signal receiving system comprises a positioning vest (1), an outer power supply (14), a computer (12), an analog-to-digital conversion interface and outer transducers (2). Digestive tract functions of personnel can be detected under the precondition of avoiding influence on the normal life of people, so that early warning on digestive tract pathological changes can be achieved in the case of abnormity of gastrointestinal motor functions.

The invention provides a pharmaceutical composition for treating upper digestive tract ulcer and its preparing process, wherein the raw materials of the medicinal constituents mainly include dandelion and bletilla tuber by a predetermined weight ratio. The composition can be made into any clinically and pharmaceutically acceptable dose forms, preferably oral preparations. The medicinal composition has the effects of protecting gastric mucosa, heat clearing, detoxicating and haemostasis.

The invention relates to the technical field of immunodiagnosis, and discloses colloidal gold immunochromatography test paper for rapidly diagnosing hemoglobin and haptoglobin hemoglobin complex and apreparation method thereof, aiming at the problem of inaccurate detection result caused by easy damage of pepsase to hemoglobin in digestive tracts in the prior art. The method specifically comprisesthe following steps: 1) preparing a first detection line T and a first quality control line C; 2) preparing a second detection line T and a second quality control line C; 3) preparing a gold-labeledpad; 4) preparing the test paper: sequentially connecting and assembling the water absorption pad, the sample pad, the microsphere probe treatment pad, the antibody-coated modified nitrocellulose membrane and the PVC bottom plate to obtain a finished product. The hemoglobin and hemoglobin combined globin compound is adopted for combined detection, the detection sensitivity of occult blood including upper gastrointestinal hemorrhage is improved, operation is easy, convenient and rapid, the result is visually and accurately displayed, sensitivity is high, specificity is good, and the preparationprocess is simple.

The invention provides a traditional Chinese medicine preparation capable of improving a contrast effect of a digestive tract; the traditional Chinese medicine preparation comprises the pharmaceutical raw materials: alum, calcined ochre, calcined ossa draconis, calcined oyster, sepiae endoconcha, limonite, raw rhubarb, fructus aurantii immaturus, magnolia officinalis, natrii sulfas, poria cocos, rhizoma pinelliae preparatum, roasted atractylodis macrocephalae rhizoma, bletillac rhizoma, pericarpium citri reticulatae, and radix glycyrrhizae preparata. The traditional Chinese medicine preparation applies the pure traditional Chinese medicine formula; through a large number of clinical and theoretical studies, toxicology experiments and animal experiments, the obtained traditional Chinese medicine preparation has good efficacies of reducing the gastric mucus content and improving the gastrointestinal peristalsis functions, effectively improves the clarity of the contrast effect in an upper digestive tract, reduces the contrast agent residual amount and time, effectively improves the digestive tract symptoms caused by a contrast agent, and brings the gospel for patients with clinical mass adoption of the digestive tract radiography technology for diagnosis of disease.

The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a monoamine reuptake inhibitor such as buproprion.

The medicine for treating tumor in upper digestive tract is prepared with white atractylodes rhizome, Chinese yam, rehmannia root, broom cypress, bitter orange and other five kinds of Chinese medicinal materials. The medicine can raise body's disease resistance, and nourish and regulate stomach. When the medicine is used in treating oesophagus cancer before and after radiotherapy, the medicine materials may have angelica, Chuanxiong rhizome and haw added. The present invention has high curative effect on upper digestive tract tumors, including oesophagus cancer, cardia cancer and gastric cancer.

The invention discloses a digestive tract connector for reconstructing a digestive tract in duodenectomy. The digestive tract connector is used for anastomosing of a pancreatic gland, a common bile duct, a stomach and an empty intestine when the digestive tract is reconstructed in the duodenectomy, and comprises a connector main body, wherein the connector main body has a pipe-shaped appearance; one end of the connector main body is relatively large and the other end of the connector main body is relatively small; the relatively large end of the connector main body is anastomosed with the stomach of a human body; the relatively small end of the connector main body is anastomosed with the empty intestine of the human body; a bile duct anastomosing tube and a pancreatic gland anastomosing tube are arranged on a side wall of the connector main body; one end of the bile duct anastomosing tube is communicated with the connector main body and the other end of the bile duct anastomosing tube is anastomosed with the bile duct of the human body. One end of the pancreatic gland anastomosing tube is communicated with the connector main body and the other end of the pancreatic gland anastomosing tube is anastomosed with the pancreatic gland of the human body. According to the digestive tract connector disclosed by the invention, the anastomosing of the pancreatic gland, the common bile duct, the stomach and the empty intestine can be rapidly finished, the surgery time is shortened and injuries to patients in surgeries are reduced.

The invention belongs to the technical field of hair growth promotion. The invention provides a plant extract solution for promoting hair growth. The plant extract solution is an alcohol solution of aplant extract, wherein the plant extract is a fructus gardenia and / or rhizoma dioscoreae althaeoidis plant extract. The fructus gardenia a has the effects of purging fire, relieving restlessness, clearing heat and promoting diuresis, cooling blood and dissipating stasis, and is clinically used for fever and restlessness, acute jaundice type hepatitis, cystitis, hot eyes and swelling pain, upper digestive tract bleeding and the like. Rhizoma dioscoreae althaeoidis is capable of relaxing tendons and activating blood, relieving cough and resolving phlegm, dispelling wind and relieving pain, andpharmacological research shows that the rhizoma dioscoreae althaeoidis has the effects of relieving cough, relieving asthma, tonifying kidney and the like. According to the extract solution, the alcohol solution of the single fructus gardenia extract, the alcohol solution of the single rhizoma dioscoreae althaeoidis extract and the alcohol solution of the extract compositions of the two are applied to the hair growth study, and a significant hair growth effect is exhibited, wherein the hair growth effect of the alcohol solution of the extract composition is more significant.

The invention discloses a coccinia grandis leaf beverage and a preparation method thereof. The beverage is mainly prepared from coccinia grandis leaf water extract and water. The preparation method comprises the following steps: selecting coccinia grandis leaves; washing and airing to remove the water; then flatly spreading and carrying out fixation at certain temperature for 1 to 2 hours; coolingto room temperature; pulping the coccinia grandis leaves and pure water; filtering, and adding stevioside and potassium sorbate into coccinia grandis leaf extract according to a certain ratio; addingthe pure water and diluting for 1 to 10 times; then filtering and sterilizing through an ultrahigh-temperature instant sterilization technology; filling and sealing under a sterile condition. According to the coccinia grandis leaf beverage disclosed by the invention, raw materials are pure natural and have no pollution; the coccinia grandis leaf beverage has a fragrant flavor, a fresh mouthfeel and low calories; the stevioside is not digested and absorbed by human bodies on upper digestive tracts; after the stevioside is mainly decomposed into steviol by caecum microorganisms on lower digestive tracts, part of the steviol is absorbed.

The present invention relates to a method of treating diabetes type II by delivery of butyric acid, bile acid, long chain fatty acid or glutamine to the colon by bypassing the upper digestive tract. The composition is combined either by the same or different route of administration with a DPP-IV inhibitor such as vildagliptin.

The present invention relates generally to detection of occult blood. In particular, the present invention provides a device and methods for the simultaneous detection of hemoglobin and transferrin in fecal samples, which permit a more sensitive diagnosis of occult blood in fecal sample and a differential diagnosis of bleeding of the upper GI tract versus the lower GI tract.

The invention discloses an upper alimentary canal endoscopy lower peeling operation training model, which comprises a housing, a middle cavity set inside the housing, and a negative pressure pump connected with the middle cavity; the middle cavity can be opened or closed and can be used to dispose an animal alimentary canal; one end of the middle cavity is provided with an alimentary canal upper end fixing apparatus and the outlet at the end is communicated with the operation inlet of the housing, and the other end of the middle cavity is provided with an alimentary canal lower end fixing apparatus and the outlet at the other end is communicated with outside. According to the model, the operation can be observed dynamically; the endoscopy operation personnel can perform more lifelike; and repeated training on a plurality of equipment and operation apparatus can be realized.

The invention relates to the field of protein-dense liquid nutritional compositions for use in the treatment and / or prevention of a condition linked to loss of muscle mass and / or strength. Provided is a heat-treated liquid high-protein composition comprising at least 10 g of protein per 100 ml of the composition, wherein at least 40 wt. % of the protein is micellar casein and at least 10 wt. % of the protein is hydrolysed whey protein having a degree of hydrolysation of at least 5%, and wherein the weight ratio of micellar casein to hydrolysed whey protein is in the range of 40:60 to 90:10, for use in any one or more of the following:a) preventing or reducing coagulation in the upper gastro-intestinal tract;b) increasing the rate of gastric emptying;c) enhancing protein digestion;d) increasing the blood serum concentration of free essential amino acids, preferably leucine, in a subject.